Tracking C3 glomerulopathy and IC-MPGN outcomes in Russia
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tracks the long-term health of people with C3 glomerulopathy or IC-MPGN, two rare kidney diseases. It does not test a new treatment, but instead collects information from medical records to better understand how these conditions progress over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child must have a confirmed diagnosis of C3 glomerulopathy or IC-MPGN (a rare kidney disease where proteins build up in the kidneys).
- You must be willing to sign a consent form (or have a parent/guardian sign it if you are under 18).
- Your kidney function must be at least 30% of normal (measured by a blood test or special formula).
- Your kidney biopsy must have been done between March 2024 and 11 months before you sign the consent form.
- You cannot be taking part in another clinical trial that tests an experimental drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial collects medical data and blood/urine samples from patients with minimal change disease or focal segmental glomerulosclerosis (FSGS) to better understand how the immune system damages kidney cells.
This study looks at how well pegcetacoplan works and how safe it is for people with two rare kidney diseases, called C3G and IC-MPGN. It will help doctors understand how the medicine helps patients in real life, outside of a strict clinical trial.
This study tests an experimental drug called SGB-9768 for people with certain kidney diseases that involve complement protein deposits. The goal is to see if it can reduce kidney damage and protein loss in urine.
This study tests an experimental drug called OMS906 for people with C3G or ICGN (immune-related kidney diseases). It aims to see if the drug is safe and can reduce kidney damage. You may qualify if you have a confirmed diagnosis, high protein in your urine, and stable kidney function.
This Phase 3 trial looks at how well and how safely iptacopan works over the long term for people with C3G or IC-MPGN. You may be able to join if you already finished a specific earlier study and you’re currently healthy enough for long-term treatment.
This trial studies whether iptacopan can improve outcomes and safety for people with C3 glomerulopathy, a kidney disease caused by overactive parts of the immune system. Participants must already be on standard kidney-protecting medicines and meet specific kidney function and urine protein criteria.
Hear when a new Kidney Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.